Stocks
GlaxoSmithKline (GSK) R&D/CAPEX US GAAP (year values) |
|||||||||
| 2022 | 2022 | 2022 | 2023 | 2023 | LTM ? | CAGR 5 years ? | |||
| R&D/CAPEX, % | 243.0% | 243.0% | 243.0% | 265.4% | 265.5% | 212.7% | |||
| Changes by years, y/y, % | +63pp | 0pp | 0pp | +22pp | +0pp | +4.1% | |||
GlaxoSmithKline. R&D/CAPEX, %
GlaxoSmithKline. R&D/CAPEX, changes, pp
GlaxoSmithKline (GSK) R&D/CAPEX US GAAP (quarter values) |
||||||||
| 2024Q2 | 2024Q1 | 2024Q3 | 2024Q2 | 2024Q3 | LTM ? | |||
| R&D/CAPEX, % | 323.1% | 243.9% | 173.3% | 323.1% | 173.3% | 212.7% | ||
| Changes by years, y/y, % | +72pp | +6pp | -144pp | +72pp | -144pp | |||
| Changes by quarters, q/q, % | +61pp | -79pp | -71pp | +150pp | -150pp | |||
